KRAS and colorectal cancer: While inhibition of constitutive ERK1/2 signaling has limited effect in KRAS‐mutant colorectal cancer patients due to compensatory pathway activation, we found that combined inhibition of RAD51 and MEK1/2 significantly increases apoptosis by inducing DSBs.